A randomised comparison of deferasirox versus deferoxamine for the treatment of transfusional iron overload in sickle cell disease.
about
Treatments for hereditary haemochromatosis: a network meta-analysisDeferasirox for managing transfusional iron overload in people with sickle cell diseaseDeferasirox for managing transfusional iron overload in people with sickle cell diseaseEvaluation of a new tablet formulation of deferasirox to reduce chronic iron overload after long-term blood transfusionsSickle cell disease in childrenPharmacology of iron transportPharmacogenetic study of deferasirox, an iron chelating agentInterventions for hereditary haemochromatosis: an attempted network meta-analysis.Fanconi syndrome in a patient with β-thalassemia major after using deferasirox for 27 months.Deferasirox (Exjade) significantly improves cardiac T2* in heavily iron-overloaded patients with beta-thalassemia major.Tailoring iron chelation by iron intake and serum ferritin: the prospective EPIC study of deferasirox in 1744 patients with transfusion-dependent anemias.Iron overload in sickle cell disease.Advances in iron chelation therapy: transitioning to a new oral formulation.Trends in blood transfusion among hospitalized children with sickle cell disease.Iron chelation therapy with deferasirox results in improvement of liver enzyme level in patients with iron overload-associated liver dysfunction.Discontinuing prophylactic transfusions increases the risk of silent brain infarction in children with sickle cell disease: data from STOP II.Cardiac iron across different transfusion-dependent diseases.Iron chelation therapy in myelodysplastic syndromes.Iron overload cardiomyopathy: better understanding of an increasing disorder.Design of iron chelators with therapeutic application.Organizing national responses for rare blood disorders: the Italian experience with sickle cell disease in childhood.A phase 1/2, dose-escalation trial of deferasirox for the treatment of iron overload in HFE-related hereditary hemochromatosisIron-chelating therapy for transfusional iron overloadLong-term safety and efficacy of deferasirox (Exjade) for up to 5 years in transfusional iron-overloaded patients with sickle cell disease.The role of galenic innovation in improving treatment compliance and persistence: three case studies.Response of iron overload to deferasirox in rare transfusion-dependent anaemias: equivalent effects on serum ferritin and labile plasma iron for haemolytic or production anaemias.Management of transfusional iron overload - differential properties and efficacy of iron chelating agents.Real-life experience with liver iron concentration R2 MRI measurement in patients with hemoglobinopathies: baseline data from LICNET.Disparity in the management of iron overload between patients with sickle cell disease and thalassemia who received transfusions.Abnormal transcranial Döppler ultrasonography in children with sickle cell disease.An update on iron chelation therapyBrazilian Guidelines for transcranial doppler in children and adolescents with sickle cell disease.Efficacy and safety of deferasirox at low and high iron burdens: results from the EPIC magnetic resonance imaging substudy.Management of the thalassemiasLight and shadows in the iron chelation treatment of haematological diseases.Hematopoietic cell transplantation: a curative option for sickle cell disease.Ethical issues and risk/benefit assessment of iron chelation therapy: advances with deferiprone/deferoxamine combinations and concerns about the safety, efficacy and costs of deferasirox.Iron overload disorders: treatment options for patients refractory to or intolerant of phlebotomy.Deferasirox: appraisal of safety and efficacy in long-term therapy.Advances in clinical research in sickle cell disease.
P2860
Q24186874-974495B3-EC55-403F-B74C-E93AC0BD8731Q24194549-C2387D50-F99C-4290-9F7E-4D6D0879CA7FQ24236463-FFE94119-CA13-4A9A-B1D7-D7204DBCC889Q26765306-F58831E5-FBBE-4DE1-8A1B-A66378822A1BQ26864582-213990F1-C72A-477D-8987-62B643227362Q27009387-3F239260-2899-4C12-8459-D19C54C60F57Q28533457-0F67B0F1-1903-438D-B965-461E21D69E92Q30399628-03CF5DAE-5FAD-43CA-9758-BF1F7FB84350Q33392822-62F2B4E5-BB90-450C-95BD-C92353B9402DQ33670385-5AAC2544-DD6A-4CDA-AE4E-EC860851F046Q33801826-C51C6DC4-6C49-4903-AC52-6A064FA86D58Q33861129-4767253C-A8A9-4339-9A8A-0CE0BB94BAFAQ33879123-6DD9D186-7983-443F-9420-22A6837E034BQ33881818-F38A6C80-39C4-4FBA-896D-1814B5A5709EQ33889442-C3D832B8-2D67-4562-B97E-436565D013E6Q33919537-8E2382D2-830F-4723-8D9E-D0B303BF15A3Q33958560-2AC5C662-AF8D-403E-8BBC-D3EB909E5D29Q34002840-1F66AF7F-2FC0-4E24-BF8C-148A4DE52040Q34165921-9DE6054C-5456-4304-8970-BE2E239288B9Q34258805-A65CF816-538A-481F-8BA7-44BCBAAF4932Q34508200-C223991F-EA5E-4675-A745-E0C5E8686D21Q34553682-D445DF27-7A3B-4964-ACD1-67B04B5EA8D1Q34806460-B11A4F47-824C-4B9E-8EEC-CA3CB170E105Q35206809-58164682-DB03-4550-9757-B701605A360FQ35454381-BAD15A26-7FF7-4950-B798-01CBF5992C6AQ35589756-43986FA3-F347-4EB0-895C-1C565FD9393AQ35683841-6B101FDC-7E18-489C-9118-24B4A6014405Q35906193-C64AE745-393A-4AB1-96C7-711D8D836BF1Q36185410-5DD6B31D-85D7-4CA5-A4CC-9538A76090BCQ36286034-AF06BD16-C660-4311-A1ED-17E9C76442EDQ36393446-DC9F8560-BFBD-46F8-8350-510399A548D0Q36464335-49E378CC-0BAE-4E9E-9DFF-B55D0F60FC96Q36524624-B37C3CBB-816F-43F3-91C8-EA6C12B25317Q36870253-61A2CB2B-28D1-49D2-B8FF-1E7DAC1506C1Q36894343-852A49FD-D590-4CE8-9062-F54A57DC6328Q37037510-F47976ED-D03F-480F-8702-0806437F6CD3Q37084711-E22912E1-70C6-4442-ACBA-4601A83CAACBQ37092252-E1B34C87-6C88-4723-AF9E-E996E3B53C55Q37095523-2696B5C3-64E7-4E2E-94ED-6E1ED1D1081CQ37110303-ADCA2250-E4AD-4663-8B0F-47D36C75BCF8
P2860
A randomised comparison of deferasirox versus deferoxamine for the treatment of transfusional iron overload in sickle cell disease.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
A randomised comparison of def ...... erload in sickle cell disease.
@ast
A randomised comparison of def ...... erload in sickle cell disease.
@en
type
label
A randomised comparison of def ...... erload in sickle cell disease.
@ast
A randomised comparison of def ...... erload in sickle cell disease.
@en
prefLabel
A randomised comparison of def ...... erload in sickle cell disease.
@ast
A randomised comparison of def ...... erload in sickle cell disease.
@en
P2093
P2860
P1476
A randomised comparison of def ...... verload in sickle cell disease
@en
P2093
Beatrice Files
Brigitta U Mueller
Catherine Ressayre-Djaffer
Daniele Alberti
Deferasirox in Sickle Cell Investigators
Ellen Fung
Elliott Vichinsky
Felicia Wilson
Françoise Bernaudin
Gian Luca Forni
P2860
P304
P356
10.1111/J.1365-2141.2006.06455.X
P407
P577
2007-02-01T00:00:00Z